Entera Bio (NASDAQ:ENTX) Stock Price Up 1.1% – Still a Buy?

Entera Bio Ltd. (NASDAQ:ENTX)’s stock price shot up 1.1% during trading on Monday . The stock traded as high as $2.75 and last traded at $2.72. 176,489 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 1,127,563 shares. The stock had previously closed at $2.69.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Entera Bio in a research note on Monday, November 11th.

Entera Bio Trading Up 1.1 %

The firm’s 50-day simple moving average is $1.93 and its two-hundred day simple moving average is $1.84. The stock has a market capitalization of $97.34 million, a PE ratio of -10.46 and a beta of 1.49.

Institutional Investors Weigh In On Entera Bio

A hedge fund recently raised its stake in Entera Bio stock. Parkman Healthcare Partners LLC grew its position in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 2.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 411,076 shares of the company’s stock after buying an additional 9,558 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 1.15% of Entera Bio worth $781,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 14.11% of the stock is currently owned by institutional investors.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.